Xortx Therapeutics Stock Net Income
| XRTX Stock | USD 0.95 0.02 2.15% |
XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.
XORTX |
XORTX Therapeutics Company Net Income Analysis
XORTX Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current XORTX Therapeutics Net Income | (2.16 M) |
Most of XORTX Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XORTX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, XORTX Therapeutics reported net income of (2.16 Million). This is 100.63% lower than that of the Biotechnology sector and 103.08% lower than that of the Health Care industry. The net income for all United States stocks is 100.38% higher than that of the company.
XORTX Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XORTX Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XORTX Therapeutics could also be used in its relative valuation, which is a method of valuing XORTX Therapeutics by comparing valuation metrics of similar companies.XORTX Therapeutics is currently under evaluation in net income category among its peers.
XORTX Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 715 K | ||||
| Shares Outstanding | 3.22 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 6.03 % | ||||
| Number Of Shares Shorted | 92.93 K | ||||
| Price To Earning | 170.67 X | ||||
| Price To Book | 1.44 X | ||||
| EBITDA | (4.87 M) | ||||
| Net Income | (2.16 M) | ||||
| Cash And Equivalents | 13.42 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 11.51 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.09 X | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (6.58 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | 0.12 X | ||||
| Price To Earnings To Growth | 9.08 X | ||||
| Target Price | 12.17 | ||||
| Beta | -0.21 | ||||
| Market Capitalization | 4.34 M | ||||
| Total Asset | 5.47 M | ||||
| Retained Earnings | (23.66 M) | ||||
| Working Capital | 3.77 M | ||||
| Current Asset | 341.74 M | ||||
| Current Liabilities | 109.37 M | ||||
| Net Asset | 5.47 M |
About XORTX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.